Christian G. Hartinger

TL;DR: In this article, a review highlights the progress in the development of ruthenium(II)/(III) complexes with flavone derivatives as potential therapeutic agents, focusing on natural hydroxyflavone derivatives and their synthetic amino analogues as ligands in Ru complexes which demonstrate antimicrobial, antitumor activity and enzyme inhibition.

TL;DR: In this article, various aspects of bio-organometallic chemistry are introduced, with the main emphasis on medicinal organometallic compounds, and rational ligand design has led to new improved therapies much in the same way that a chemist working in catalysis will design new ligands for improved activities.

TL;DR: It was surprisingly found that only the Rh complexes showed significant inhibitory activity at IC50 values of ∼1 μM, independent of the substituents on the NHC ligand, indicating that, although TrxR may be a potential target for anticancer metal complexes, it is unlikely the main target or the sole target for the Ru, Os, and Ir compounds described here, and other targets should be considered.

TL;DR: Capillary electrophoresis is described as a versatile tool for the characterization of specific metal‐bioligand binding products and thereby for providing mechanism‐of‐action information and the current limitations of CE in the field are brought into focus.